End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
19.98 CNY | -1.67% | -1.33% | -19.63% |
Apr. 30 | Humanwell Healthcare's Q1 Profit Falls 27% | MT |
Apr. 29 | Humanwell Healthcare Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.63% | 4.45B | B- | ||
+32.95% | 698B | C+ | ||
+26.51% | 568B | B | ||
-4.97% | 358B | C+ | ||
+18.83% | 328B | B- | ||
+3.54% | 283B | C+ | ||
+16.08% | 238B | B+ | ||
+6.68% | 203B | B- | ||
-9.08% | 198B | A+ | ||
+6.70% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600079 Stock
- Ratings Humanwell Healthcare (Group) Co.,Ltd.